Accent Microcell Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/decsqslq6ap9fp3hxng2feib.pdf

Key Takeaways


Unit 3 Expansion: The Growth Engine

Ghanshyam Patel: "We already have orders for this amount, and we will supply the same to our existing customers worldwide."

Margin Trajectory

Ghanshyam Patel: "We would then look forward to a better EBITDA margin, even from the MCC, like-to-like."

Product & Customer Evolution


Current Operations & Constraints

Ghanshyam Patel: "At this precise moment we do not see any tariff being levied on our products or on the product we are manufacturing. But just in case if anything turns up in the future, we have a plan which we are working on, so that will be taken care of."

Regulatory & Disclosure Boundaries


Guidance & Commitments

CommitmentSpecificsTimeline
Unit 3 Phase 1 commercial productionCCS, CMC, SSG production beginsSeptember–October 2025
Unit 3 Phase 2 commercial productionMCC production begins~June 2026
Phase 1 year-one revenue~₹70 crore (from ~6 months of operations in H2 FY26)FY26 (H2)
Phase 1 peak revenue₹150–160 croreBy FY28
Phase 2 standalone revenue₹220–250 crorePost-Phase 2 commercialization
Phase 1 utilization ramp~45% in year 1, ~70% in year 2, maximum in year 3FY26–FY28
Unit 3 standalone bottom-line margin~25% (conservative basis)Once Unit 3 is commercialized
Combined asset-turnover ratioNot less than 4.5–5× for Phase 1 + Phase 2Post-Phase 2
Phase 2 margin improvementBetter EBITDA margins on MCC by eliminating outsourced semi-finished goodsOnce Phase 2 is operational
Related-party transactionsExpected to reach negligible levelsNear future
Equity dilutionNone foreseen; balance of project cost from internal accrualsThrough expansion cycle

Key Metrics

MetricQ4 FY25 / FY25
Revenue from operations₹265 cr, +8% YoY
PAT₹33 cr, +10% YoY
EBITDA+12% YoY
EBIT marginUnchanged YoY
Operating (EBITDA) margin15%–16% on a consolidated basis
PAT margin12%–13%
Export revenue share53.49%, balance domestic
BorrowingsSignificant drop compared with previous year
Unit-1 (Piranha) capacity utilization100%
Unit-2 (SEZ) capacity utilization95%
Combined installed capacity (Unit 1 + Unit 2)9,200 metric tons per annum
Total quantity sold in FY25~12,000 metric tons (9,000 metric tons in-house manufactured, ~2,500–3,000 metric tons semi-finished goods procured and further processed)
Premium-range revenue share~10% of revenue, balance from MCC
Premium product realization vs MCC3.5× to 4× the prevailing market price of MCC
Unit-3 Phase 1 commercial production startSeptember–October 2025
Unit-3 Phase 1 peak revenue₹150–160 cr
Unit-3 Phase 1 year-one revenue~₹70 cr (at ~45–50% utilization, ~6 months of operations)
Unit-3 Phase 2 commercialization~June 2026
Unit-3 Phase 2 peak revenue₹220–250 cr on a standalone basis
Unit-3 Phase 1 capex~₹55 cr
Unit-3 Phase 2 capex~₹55–60 cr
Rights issue approval amountUp to ₹940 cr
Export vs domestic margin differential~10%
Debtors-to-sales ratio24.52, up from 21.91
Cash-conversion cycleIncreased by 10 days
Pharma segment share of finished goods65–75%
Food and nutra segment share~15%
Technical grades share10–15%
Contingent liability (NGT penalty)₹4.11 cr, classified as remote